JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the completion of its 1,000th commercial Trilogy procedure, performed in ...
() -Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug. The drugmaker struck a deal worth nearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback